Latest news and press releases about 10x Genomics, Inc. (TXG): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
Price
| Price | $97.74 |
| Market Cap | $12.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 15.39 |
| EV / EBITDA | 427.97 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -9.33% |
| Return on Invested Capital | -9.57% |
| Return on Assets | -7.29% |
| Gross Margin | 70.03% |
| Operating Margin | -14.33% |
| Net Margin | -12.18% |
Related companies: CERT · GRDN · JANX · NUVB · OMCL · OMDA · PGNY
Explore sector: Healthcare · Biotechnology
More sections of TXG: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks